MDxHealth is trading at $0.19, down 6.34% in after-hours trading after suspending 2026 guidance following a Q3 revenue shortfall.
- Preliminary Q3 revenue was approximately $22.7 million, flat year over year, and fell short of expectations.
- Management suspended its $110–115 million full-year 2026 revenue guidance and cited unexpected sales-force turnover after discontinuing Resolve mdx.
- Full Q3 results are scheduled for November 12.